BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25742790)

  • 1. Induction of cellular prion protein (PrPc) under hypoxia inhibits apoptosis caused by TRAIL treatment.
    Park JY; Jeong JK; Lee JH; Moon JH; Kim SW; Lee YJ; Park SY
    Oncotarget; 2015 Mar; 6(7):5342-53. PubMed ID: 25742790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
    PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
    Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
    Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-inducible factor-1 α regulates prion protein expression to protect against neuron cell damage.
    Jeong JK; Seo JS; Moon MH; Lee YJ; Seol JW; Park SY
    Neurobiol Aging; 2012 May; 33(5):1006.e1-10. PubMed ID: 22036844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia inducing factor-1alpha regulates tumor necrosis factor-related apoptosis-inducing ligand sensitivity in tumor cells exposed to hypoxia.
    Jeong JK; Moon MH; Seo JS; Seol JW; Park SY; Lee YJ
    Biochem Biophys Res Commun; 2010 Aug; 399(3):379-83. PubMed ID: 20659427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
    Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
    FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation.
    Tanaka H; Hoshikawa Y; Oh-hara T; Koike S; Naito M; Noda T; Arai H; Tsuruo T; Fujita N
    Mol Cancer Res; 2009 Apr; 7(4):557-69. PubMed ID: 19372584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes.
    Lin T; Gu J; Zhang L; Huang X; Stephens LC; Curley SA; Fang B
    Cancer Res; 2002 Jul; 62(13):3620-5. PubMed ID: 12097263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
    Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
    Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells.
    Kim DR; Park MY; Lee CS; Shim SH; Yoon HI; Lee JH; Sung MW; Kim YS; Lee CT
    Cancer Gene Ther; 2011 Jul; 18(7):467-77. PubMed ID: 21455254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand.
    Fecker LF; Rückert S; Kurbanov BM; Schmude M; Stockfleth E; Fechner H; Eberle J
    Hum Gene Ther; 2011 Apr; 22(4):405-17. PubMed ID: 20977303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
    Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
    Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing of cellular prion protein (PrPC) expression by DNA-antisense oligonucleotides induces autophagy-dependent cell death in glioma cells.
    Barbieri G; Palumbo S; Gabrusiewicz K; Azzalin A; Marchesi N; Spedito A; Biggiogera M; Sbalchiero E; Mazzini G; Miracco C; Pirtoli L; Kaminska B; Comincini S
    Autophagy; 2011 Aug; 7(8):840-53. PubMed ID: 21478678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients.
    Cheng Y; Tao L; Xu J; Li Q; Yu J; Jin Y; Chen Q; Xu Z; Zou Q; Liu X
    Mol Carcinog; 2014 Sep; 53(9):686-97. PubMed ID: 23681900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells.
    Zhu H; Chen XP; Luo SF; Guan J; Zhang WG; Zhang BX
    J Exp Clin Cancer Res; 2005 Dec; 24(4):565-74. PubMed ID: 16471319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor suppressor XIAP-Associated factor 1 (XAF1) cooperates with tumor necrosis factor-related apoptosis-inducing ligand to suppress colon cancer growth and trigger tumor regression.
    Tu SP; Sun YW; Cui JT; Zou B; Lin MC; Gu Q; Jiang SH; Kung HF; Korneluk RG; Wong BC
    Cancer; 2010 Mar; 116(5):1252-63. PubMed ID: 20082449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition.
    Gabellini C; De Luca T; Trisciuoglio D; Desideri M; Di Martile M; Passeri D; Candiloro A; Biffoni M; Rizzo MG; Orlandi A; Del Bufalo D
    Carcinogenesis; 2013 Nov; 34(11):2558-67. PubMed ID: 23836782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia inducible factor 1α and hypoxia inducible factor 2α play distinct and functionally overlapping roles in oral squamous cell carcinoma.
    Zhu GQ; Tang YL; Li L; Zheng M; Jiang J; Li XY; Chen SX; Liang XH
    Clin Cancer Res; 2010 Oct; 16(19):4732-41. PubMed ID: 20807755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
    Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
    Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the silencing of hypoxia-inducible Factor-1 alpha on metastasis of pancreatic cancer.
    Wei H; Li F; Fu P; Liu X
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):436-46. PubMed ID: 23467940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.